{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T03:05:38Z","timestamp":1773457538982,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA046721"],"award-info":[{"award-number":["R01DA046721"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["P30DA040500"],"award-info":[{"award-number":["P30DA040500"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jval.2025.07.008","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T16:01:45Z","timestamp":1753200105000},"page":"1461-1471","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost per Opioid-Free Year: A Systematic Review and Summary Analysis"],"prefix":"10.1016","volume":"28","author":[{"given":"Babasoji E.","family":"Oyemakinde","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Techna","family":"Cadet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tyler","family":"Judge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manesh","family":"Gopaldas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Jalali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean M.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2025.07.008_bib2","doi-asserted-by":"crossref","first-page":"108382","DOI":"10.1016\/j.drugalcdep.2020.108382","article-title":"The cost of opioid use disorder and the value of aversion","volume":"217","author":"Murphy","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.jval.2025.07.008_bib3","doi-asserted-by":"crossref","first-page":"102768","DOI":"10.1016\/j.drugpo.2020.102768","article-title":"A scoping review of barriers and facilitators to implementation of medications for treatment of opioid use disorder within the criminal justice system","volume":"81","author":"Grella","year":"2020","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.jval.2025.07.008_bib4","first-page":"100029","article-title":"A systematic literature review of patient perspectives of barriers and facilitators to access, adherence, stigma, and persistence to treatment for substance use disorder","volume":"2","author":"Cernasev","year":"2021","journal-title":"Explor Res Clin Soc Pharm"},{"issue":"5","key":"10.1016\/j.jval.2025.07.008_bib5","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1080\/14737167.2024.2350561","article-title":"Informing evidence-based medicine for opioid use disorder using pharmacoeconomic studies","volume":"24","author":"Jalali","year":"2024","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.jval.2025.07.008_bib6","series-title":"Cost-Effectiveness in Health and Medicine","author":"Neumann","year":"2017"},{"key":"10.1016\/j.jval.2025.07.008_bib7","series-title":"Clinical Trials","article-title":"Economic Evaluation","author":"Glick","year":"2014"},{"key":"10.1016\/j.jval.2025.07.008_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108221","article-title":"Health-related quality of life and opioid use disorder pharmacotherapy: a secondary analysis of a clinical trial","volume":"215","author":"Jalali","year":"2020","journal-title":"Drug Alcohol Depend"},{"issue":"9","key":"10.1016\/j.jval.2025.07.008_bib9","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness\u2014the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jval.2025.07.008_bib10","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0740-5472(92)90062-S","article-title":"The fifth edition of the addiction severity index","volume":"9","author":"McLellan","year":"1992","journal-title":"J Subst Abuse Treat"},{"issue":"5","key":"10.1016\/j.jval.2025.07.008_bib12","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2165\/00019053-200826050-00003","article-title":"Economic evaluation of interventions to treat opiate dependence: a review of the evidence","volume":"26","author":"Doran","year":"2008","journal-title":"Pharmacoeconomics"},{"issue":"9","key":"10.1016\/j.jval.2025.07.008_bib13","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s40273-016-0400-5","article-title":"Economic evaluations of opioid use disorder interventions: a systematic review","volume":"34","author":"Murphy","year":"2016","journal-title":"Pharmacoeconomics"},{"issue":"7","key":"10.1016\/j.jval.2025.07.008_bib14","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.jval.2020.12.023","article-title":"Economic evaluations of pharmacologic treatment for opioid use disorder: a systematic literature review","volume":"24","author":"Onuoha","year":"2021","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.jval.2025.07.008_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1515\/2152-2812.1114","article-title":"Skills of the trade: the tufts cost-effectiveness analysis registry","volume":"3","author":"Thorat","year":"2012","journal-title":"J Benefit Cost Anal"},{"key":"10.1016\/j.jval.2025.07.008_bib16","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jclinepi.2019.04.015","article-title":"PubMed coverage varied across specialties and over time: a large-scale study of included studies in Cochrane reviews","volume":"112","author":"Frandsen","year":"2019","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jval.2025.07.008_bib17","author":"Higgins"},{"issue":"6","key":"10.1016\/j.jval.2025.07.008_bib19","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/j.1360-0443.2004.00728.x","article-title":"Cost and cost-effectiveness of standard methadone maintenance treatment compared to enriched 180-day methadone detoxification","volume":"99","author":"Masson","year":"2004","journal-title":"Addiction"},{"issue":"2","key":"10.1016\/j.jval.2025.07.008_bib20","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jsat.2010.05.012","article-title":"The cost of concordance with opiate substitution treatment guidelines","volume":"39","author":"Barnett","year":"2010","journal-title":"J Subst Abuse Treat"},{"key":"10.1016\/j.jval.2025.07.008_bib21","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jsat.2018.07.014","article-title":"Re-engineering methadone\u2014cost-effectiveness analysis of a patient-centered approach to methadone treatment","volume":"94","author":"Dunlap","year":"2018","journal-title":"J Subst Abuse Treat"},{"issue":"9","key":"10.1016\/j.jval.2025.07.008_bib22","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1111\/j.1360-0443.2010.03001.x","article-title":"Cost-effectiveness of extended buprenorphine-naloxone treatment for opioid-dependent youth: data from a randomized trial","volume":"105","author":"Polsky","year":"2010","journal-title":"Addiction"},{"issue":"1","key":"10.1016\/j.jval.2025.07.008_bib23","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3109\/15360288.2015.1135847","article-title":"Office-based buprenorphine versus clinic-based methadone: a cost-effectiveness analysis","volume":"30","author":"King","year":"2016","journal-title":"J Pain Palliat Care Pharmacother"},{"issue":"8","key":"10.1016\/j.jval.2025.07.008_bib24","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1111\/add.13807","article-title":"Cost-effectiveness of extended release naltrexone to prevent relapse among criminal justice-involved individuals with a history of opioid use disorder","volume":"112","author":"Murphy","year":"2017","journal-title":"Addiction"},{"key":"10.1016\/j.jval.2025.07.008_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2022.108835","article-title":"Cost-effectiveness of extended-release injectable naltrexone among incarcerated persons with opioid use disorder before release from prison versus after release","volume":"141","author":"Jalali","year":"2022","journal-title":"J Subst Abuse Treat"},{"issue":"2","key":"10.1016\/j.jval.2025.07.008_bib26","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1080\/08897077.2015.1010031","article-title":"Cost-effectiveness of injectable extended-release naltrexone compared with methadone maintenance and buprenorphine maintenance treatment for opioid dependence","volume":"36","author":"Jackson","year":"2015","journal-title":"Subst Abus"},{"issue":"2","key":"10.1016\/j.jval.2025.07.008_bib27","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.drugalcdep.2006.01.010","article-title":"Value for money in drug treatment: economic evaluation of prison methadone","volume":"84","author":"Warren","year":"2006","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"10.1016\/j.jval.2025.07.008_bib28","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2165\/00019053-200523010-00007","article-title":"A randomised trial of the cost effectiveness of buprenorphine as an alternative to methadone maintenance treatment for heroin dependence in a primary care setting","volume":"23","author":"Harris","year":"2005","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"10.1016\/j.jval.2025.07.008_bib29","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1080\/09595230701373883","article-title":"The costs and consequences of three policy options for reducing heroin dependency","volume":"26","author":"Moore","year":"2007","journal-title":"Drug Alcohol Rev"},{"issue":"12","key":"10.1016\/j.jval.2025.07.008_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0050673","article-title":"Cost-effectiveness of buprenorphine and naltrexone treatments for heroin dependence in Malaysia","volume":"7","author":"Ruger","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jval.2025.07.008_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102311","article-title":"Superiority and cost-effectiveness of monthly extended-release buprenorphine versus daily standard of care medication: a pragmatic, parallel-group, open-label, multicentre, randomised, controlled, phase 3 trial","volume":"66","author":"Marsden","year":"2023","journal-title":"EClinicalmedicine"},{"issue":"4","key":"10.1016\/j.jval.2025.07.008_bib32","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1586\/14737167.6.4.437","article-title":"Cost-effectiveness analysis of maintenance agonist treatments in the NEPOD","volume":"6","author":"Doran","year":"2006","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"4","key":"10.1016\/j.jval.2025.07.008_bib33","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s40273-014-0136-z","article-title":"Estimating QALY gains in applied studies: a review of cost-utility analyses published in 2010","volume":"32","author":"Wisl\u00f8ff","year":"2014","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"10.1016\/j.jval.2025.07.008_bib34","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/MLR.0b013e31815c31a7","article-title":"What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?","volume":"46","author":"Braithwaite","year":"2008","journal-title":"Med Care"},{"issue":"3","key":"10.1016\/j.jval.2025.07.008_bib35","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1007\/s11606-018-4738-6","article-title":"Practical guidance for involving stakeholders in Health Research","volume":"34","author":"Concannon","year":"2019","journal-title":"J Gen Intern Med"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301525024738?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301525024738?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T02:27:07Z","timestamp":1773455227000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301525024738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1098301525024738"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2025.07.008","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost per Opioid-Free Year: A Systematic Review and Summary Analysis","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2025.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}